baber/WOPTO huggingface dataset:
Patent NZ-209508-A (NZ)
Title: Removing steroids and/or pharmaceutically active compounds from fats and oils
Inventor: KEEN A R
IPC: C11B3/10
Filed: 1984-09-11
Abstract: Compounds at least one of which is a selected compound specifically cholesterol are removed from fats or oils specifically anhydrous milk fat by passing liquid fat or oil over an absorbent or adsorbent material specifically granulated active carbon.
Patent NZ-215208-A (NZ)
Title: Animal goggles
Inventor: PELLING MICHAEL GERARD
IPC: A01K13/00
Filed: 1986-02-18
Abstract: PCT No. PCT/AU86/00034 Sec. 371 Date Oct. 17, 1986 Sec. 102(e) Date Oct. 17, 1986 PCT Filed Feb. 11, 1986 PCT Pub. No. WO86/04886 PCT Pub. Date Aug. 28, 1986.Animal goggles include a flexible hood for fitting closely and being secured on an animal's head, and with eye holes to each of which is fitted a mesh eye guard projecting forwardly from the periphery of the eye hole. The periphery of each eye guard is outwardly flanged for releasable engagement in an annnular recess formed from the inner periphery of a flexible and resiliently deformable edging ring about each eye hole, and associated with each edging ring is an arcuate retainer in which the base of a blindker may be removably engaged to the outer side of the eye hole and eye guard.
Patent NZ-218368-A (NZ)
Title: Tetraenyl prostaglandins and pharmaceutical compositions containing such
Inventor: COLLINS P W
IPC: C07C405/00
Filed: 1986-11-21
Abstract: This invention encompasses prostaglandins of the for- mJlawherein R represents hydrogen or lower alkyl having 1 to 6 carbon atoms; R, represents hydrogen, vinyl, or lower alkyl having 1 to 4 carbon atoms and the wavy line represents R or S stereochemistry; R<sub>2</sub>, R<sub>3</sub>, and R<sub>4</sub> are hydrogen or lower alkyl having 1 to 4 carbon atoms or R<sub>2</sub> and R<sub>3</sub> together with carbon Y form a cycloalkenyl having 4 to 6 carbon atoms or R<sub>3</sub> and R<sub>4</sub> together with carbons X and Y form a cycloalkenyl having 4 to 6 carbons. Compounds of this invention have potent gastric antisecretory and cytoprotective properties with unexpectedly low diarrheogenic side effects.
Patent NZ-222788-A (NZ)
Title: Process for eliminating re-entry disulphides in a mercaptan extraction process
Inventor: BRICKER JEFFERY C
IPC: C10G19/08
Filed: 1987-12-03
Abstract: Reentry disulphides are eliminated in a continuous process for treating a sour hydrocarbon stream by extracting the mercaptans contained in the hydrocarbon stream 1 with a disulphide-free alkaline solution in an extraction zone 3, oxidizing the mercaptans to disulphides in the presence of an oxidation catalyst, in oxidation zone 6, separating a major portion of the disulphides from the alkaline solution at 9, reducing the residual disulphides in the alkaline solution to mercaptans and recycling the resulting substantially disulphide-free alkaline solution from the reduction zone 12 to the extraction zone 3. The reduction of the disulphides to mercaptans may be carried out by hydrogenation or by electrochemical reduction.
Patent NZ-231822-A (NZ)
Title: Pharmaceutical aerosol formulation of sodium cromoglycate with chlorofluorocarbon propellant
Inventor: BELL HOWARD JOHN
IPC: A61K9/12
Filed: 1989-12-18
Abstract: According to the present invention there is provided a pharmaceutical composition containing 0.1-10% sodium cromoglycate by weight of the total composition with trichloromonofluoromethane in combination with any proportion of dichlorodifluoromethane and dichlorotetrafluoromethane, wherein the total water content when expressed as a proportion of anhydrous sodium cromoglycate is 2 to 14% by weight.
Patent NZ-235766-A (NZ)
Title: Package of flexible articles in compressed form
Inventor: CORNELISSEN ROGER EMIL
IPC: B65D85/08
Filed: 1990-10-19
Abstract: Paper bag dimensioned so as to compactly pack compressed flexible articles (28) and to maintain these articles in their compressed form. Furthermore, means for closing, carrying and opening the paper bags with compactly packed flexible articles (28) are disclosed.
Patent NZ-247715-A (NZ)
Title: 2-aminocyclopentane (-pentene and -methylidenepentane) carboxylic acid derivatives and pharmaceutical compositions thereof
Inventor: MITTENDORF JOACHIM
IPC: C07C61/35
Filed: 1993-05-27
Abstract: Cyclopentane- and -pentene- beta -amino acids of the general formula (I) <IMAGE>  in which   A, B, D, E, G, L, M and T are identical or different and, with the proviso that at least one of the abovementioned substituents is H, represents hydrogen, halogen, benzyl, hydroxyl or optionally substituted alkyl with up to 8 carbon atoms, or in each case B and D, E and G or L and M together represent a radical of the formula <IMAGE>     or =N-OH, or E and G and/or B and D together represent the radical of the formula =O or =S, or B, D, E and G or E, G, L and M each together form a radical of the formula <IMAGE> in which D' and G' have the abovementioned meaning of D and G, but do not both denote hydrogen and G and L have the abovementioned meaning   V is an oxygen or sulphur atom or the -NH group, R<1> is hydrogen, optionally substituted alkyl or optionally substituted phenyl or, if V is the -NH group, is the group of the formula -SO2R<8>, R<2> is hydrogen, an amino protective group customary in peptide chemistry, optionally substituted alkyl with up to 8 carbon atoms, acyl with up to 8 carbon atoms, optionally substituted benzoyl, a group of the formula -SO2R<8> or an amino acid residue of the formula   <IMAGE>   R<3> is hydrogen or optionally phenyl-substituted alkyl with up to 8 carbon atoms, or R<2> and R<3> together represent the radical of the formula =CHR<14>, process for their preparation and their use as pharmaceuticals, especially antimycotic pharmaceuticals, are described.
Patent NZ-260531-A (NZ)
Title: 2-aminopyrazin-5-carboxamide derivatives and pharmaceutical compositions
Inventor: GEORGE PASCAL
IPC: A61K31/495
Filed: 1994-05-16
Abstract: Compounds corresponding to the general formula (I) <IMAGE> in whch n represents 0 or 1, R1 represents a methyl group, in which case R2 represents a phenoxy(C1-C4)alkyl group (whose phenoxy group is optionally substituted), or alternatively R1 and R2 form together, and with the nitrogen atom carrying them, a 4-(phenoxymethyl)piperid-1-yl group (whose phenoxy group is optionally substituted), or a 4-phenylpiperazin-1-yl group (whose phenyl group is optionally substituted), R3 represents a hydrogen atom or a methyl group, R4 represents a hydrogen atom, R5 represents a hydrogen atom or a group of general formula -CH2-CH2-NH-R6, R6 being a hydrogen atom, or a tert-butyloxycarbonyl, 4-carbamoylpyrimidin-2-yl or 5-carbamoylpyrazin-2-yl group. Therapeutic application.
Patent NZ-263730-A (NZ)
Title: Production of sugars from (hemi)cellulosic materials by strong acid hydrolysis, and subsequent separation and fermentation
Inventor: FARONE WILLIAM A
IPC: C13B20/14
Filed: 1994-03-25
Abstract: An economically viable method for producing sugars using concentrated acid hydrolysis of biomass containing cellulose and hemicellulose is disclosed. The cellulose and hemicellulose in the biomass are first decrystallized and then hydrolyzed to produce a hydrolysate containing both sugars and acid. Silica present in the biomass can then be removed for further processing. The remaining solids are then subjected to a second decrystallization and hydrolyzation to optimize the sugar yields. An improved method for separating the sugars from the acid in the hydrolysate is also disclosed. The resulting sugar stream can then be fermented, using an improved method which allows both hexose and pentose sugars to be fermented simultaneously.
Patent NZ-272031-A (NZ)
Title: Substituted pyrrolo [2,3-d] pyrimidines and pharmaceutical compositions therof
Inventor: TRAXLER PETER
IPC: A61P43/00
Filed: 1995-05-01
Abstract: Use of pyrrolo(2,3-d)pyrimidine derivs. of formula (I) or their salts to prepare medicaments for treatment of tumours and other proliferative diseases, disorders of the immune system mediated by protein-tyrosine and/or protein-threonine kinases, and disorders of the central and peripheral nervous system involving signal transmission by protein-tyrosine and/or protein-threonine kinases, is new: n = 0-5; R = halo, alkyl, CF3 or alkoxy; and R1,R2 = H, alkyl, or phenyl opt. substd. by halo, CF3, alkyl or alkoxy; or R1+R2 = opt. alkyl-substd. 2-5C alkylene; provided that R1 and R2 are not both H.
Patent NZ-277562-A (NZ)
Title: Gene encoding a protein that desaturates lipid bound fatty acids at the delta 9 position
Inventor: NISHIZAWA OSAMU
IPC: C12N15/82
Filed: 1994-12-28
Abstract: A gene coding for a protein having the activity of desaturating the DELTA 9-position of a fatty acid bound to a lipid; a vector containing a polynucleotide containing the whole or part of said gene; a plant cell containing, transferred thereinto, a polynucleotide containing the whole or part of a gene coding for a protein having the activity of desaturating the  DELTA 9-position of a fatty acid bound to a lipid; a process for creating a plant which comprises differentiating said plant cells and regenerating the plant body; and a plant containing, transferred thereinto, a polynucleotide containing the whole or part of a gene coding for protein having the activity of desaturating the  DELTA 9-position of a fatty acid bound to a lipid. <IMAGE>
Patent NZ-279953-A (NZ)
Title: Lipid-polar solvent bilayer carrier preparation (eg liposomes) comprising digalactosyldiacylglycerols as the bilayer material
Inventor: CARLSSON ANDERS
IPC: A23L35/00
Filed: 1995-02-06
Abstract: A galactolipid material from wheat, produced by extraction of crushed wheat grains and subsequent chromatography of the extracted material, and having a content of DGDG of 51.5%, was mixed with the polar solvents, water and glycerol in order to test the swellability. The samples, prepared in glass tubes, were alternately mixed with a rod and centrifugated at room temperature until homogeneous. The samples were inspected as to physical appearance after storing for at least a week at room temperature. Results: 20% (w/w) of galactolipid material in water gave a slightly yellow, highly viscous dispersion. Small liposomes could be observed in a polarizing microscope. At higher galactolipid concentrations a stiff gel was formed. 10% (w/w) of the same lipid material in anhydrous glycerol resulted in the formation of an opaque, highly viscous gel.
Patent NZ-287860-A (NZ)
Title: Biodegradable glass fiber compositions
Inventor: DE MERINGO ALAIN
IPC: C03C3/091
Filed: 1995-05-24
Abstract: A biologically degradable glass-fiber composition characterized by the following constituents in percent by weight:SiO<sub>2</sub>45 to 60Al<sub>2</sub>O<sub>3</sub>less than 2CaO + MgO10 to 16Na<sub>2</sub>O + K<sub>2</sub>Omore than 18 to 23B<sub>2</sub>O<sub>3</sub>10 to 18P<sub>2</sub>O<sub>5</sub>0 to 4BaO0 to 1Diverse0 to 2.
Patent NZ-296098-A (NZ)
Title: Super oxide dismutase in liposome and it's use in therapy
Inventor: KATINGER HERMANN
IPC: A23L5/20
Filed: 1995-11-06
Abstract: A cosmetic or pharmaceutical preparation for topical administration which comprises a low-fat or fat-free carrier together with a recombinant human Cu,Zn-SOD (rhSOD) in unilamellar liposomes.  The liposomes have an average diameter of 200 nm or less and the rhSOD is present in a concentration of 0.01 to 5% by weight.  The composition is capable of penetrating the tissue and treating pathological conditions that are caused by increased concentrations of superoxide radicals and/or the damage caused thereby.  Such diseases include rheumatic joint inflammation, osteoarthritis, emphysema, bronchitis, ARDS and other similar diseases.
Patent NZ-314096-A (NZ)
Title: Tap flow controller: radial passages extend outward from central passage
Inventor: MCDONALD CHRISTOPHER WILLIAM
IPC: F16K47/08
Filed: 1997-01-21
Abstract: A flow control device (40) which is to be inserted in the valve seat of a tap. The flow control device (40) includes a threaded section (48) to threadably engage an associated tap within which the device (40) is located. The device (40) includes a passage (42) which terminates internally of the body (43). Passages (44) radiate from the passage (45) through the body to a peripheral surface (45). The end face (47) of the device (40) is intended to be engaged by the washer of the tap. <IMAGE>
Patent NZ-323008-A (NZ)
Title: A recombinant plasmid pSRQ800 containing DNA encoding a protein designated as AbiE which in Lactococcus lactis increases resistance to phages by aborting infection by phages and method and use
Inventor: MOINEAU SYLVAIN
IPC: C12N1/21
Filed: 1996-11-20
Abstract: An isolated DNA encoding a protein designated as AbiE contained in plasmid pSRQ800 which in a Lactococcus lactis increase resistance to phages by aborting infection of the Lactococcus lactis by phages. This can be deposited as NRRL-B-21443, which is in a 4.5kb EcoR1 segment contained in the plasmid pSRQ800. The DNA has the SEQ ID NO:1 which is 4467 nucleotides in length. Also claimed is a recombinant plasmid comprising pSRQ800 encoding a protein designated as AbiE, the plasmid which is a shuttle vector pSA3 or pNZ123 containing the DNA, bacterium harboring a recombinant plasmid containing DNA contained in plasmid pSRQ800 encoding a protein designated as AbiE which in a Lactococcus lactis increases resistance to phage by aborting infection of the lactis phages.
Patent NZ-330818-A (NZ)
Title: Benzo-1, 3-dioxolyl- and benzofuranyl substituted pyrrolidine derivatives as endothelin antagonists
Inventor: WINN MARTIN
IPC: A61K31/435
Filed: 1997-02-12
Abstract: A compound of formula (I), or a pharmaceutically acceptable salt thereof is disclosed, as well as processes for and intermediates in the preparation thereof, and a method of antagonizing endothelin. Endothelin has been shown to constrict arteries and veins, increase mean arterial blood pressure, decrease cardiac output, increase cardiac contractility in vitro, stimulate mitogenesis in vascular smooth muscle including guinea pig trachea, human urinary bladder strips and rat uterus in vitro, induce formation of gastric ulcers, stimulate release of atrial natriuretic factor in vitro and in vivo, increase plasma levels of vasopressin, aldosterone and catecholamines, inhibit release of renin in vitro and stimulate release of gonadotropins in vitro. The compound of formula (I) wherein, Z is -C(R18)(R19)-or -C(O)- wherein R18 and R19 are independently selected from hydrogen and lower alkyl; n is 0 or 1; R is (CH2)m-W wherein m is an integer from 0-6 and W is (a) -C(O)2-G wherein G is H or a carboxy protecting group, (b) -PO3H2, (c) -P(O)(OH)E wherein E is hydrogen, lower alkyl or arylalkyl, (d) -CN, (e) -C(O)NHR17 wherein R17 is lower alkyl, (f) alkylaminocarbonyl, (g) dialkylaminocarbonyl, (h) tetrazolyl, (i) hydroxy, (j) alkoxy, (k) sulfonamido, (l) -C(O)NHS(O)2R16 wherein R16 is loweralkyl, haloalkyl, aryl or dialkylamino, (m) -S(O)2NHC(O)R16, (n)-(u) are represented in the figures provided; R1-R25 are selected from common hydrocarbon groups.
Patent NZ-335170-A (NZ)
Title: Oral administration of chicken yolk Ig-gamma antibodies to treat disease
Inventor: COLEMAN MARILYN A
IPC: A61K39/395
Filed: 1997-10-02
Abstract: The use of Igã antibodies obtained from the egg of a domestic fowl hen which gas been actively orally  immunized against pathogenic organisms by injection of the hen with an immunogen.  The immunogen contains determinants specific to elicit antibodies for treating systemic manifestations of an infectious non-intestinal disease associated with a pathogenic organism. Also disclosed is the use if Igã antibodies in treating infectious disease associated with pathogenic organisms in an HIV-positive or immune compromised patient.
Patent NZ-335329-A (NZ)
Title: Water soluble polyether glycol polymer capable of complexing phosphate or oxalate used for reduction of dietary phosphate or oxalate absorption
Inventor: SIMON JAIME
IPC: C08G65/22
Filed: 1997-10-22
Abstract: A water-soluble polyether glycol polymer having: a structural backbone of carbon atoms and oxygen atoms where there are at least two consecutive carbon atoms present between each oxygen atom; derivatised with one or more primary or secondary polyamines, that is cationic at physiological pH and permits complexation with phosphate or oxalate. The polymer having an average molecular weight from 3,500 to 80,000 Daltons. The solubility of the polymer is at least 0.01 gram of the polymer per 1,000 ml of water. These polymers are formulated for oral dosage to reduce the phosphonate or oxalate levels in an animal. The process of preparing these polymers and the method of reducing gastrointestinal absorption of phosphate and oxalate are included.
Patent NZ-336357-A (NZ)
Title: Internet connection for plurality of users
Inventor: CUCKOV ANDREJ
IPC: H04L12/28
Filed: 1997-05-16
Abstract: A system for providing a plurality of users access to an information source (4), such as the Internet, including a plurality of computing processors (6) linked to the information source (4) through a server (18) whereby information from the information source is graphically displayed on television receivers (8), each user having access to a television receiver (8) and being assigned one of the computing processors (6) on a shared basis. The server (18) receives and transmits digital data between the information source (4) and the computing processors (6). The users can manipulate and interact with the information through a wireless keyboard (26). Conversion of digital data into analogue data associated with keyboard commands takes place through a modem (30) and interface processing unit (32) associated with each receiver (8). It is used particularly by hotel guests and hospital patients.
Patent NZ-501412-A (NZ)
Title: Oxazolidinone antibacterial agents having a thiocarbonyl functionality
Inventor: HESTER JACKSON B
IPC: A61K31/496
Filed: 1998-05-18
Abstract: Compounds of Formula (I) or pharmaceutically acceptable salts thereof are described, wherein A, G and R1 are as defined in the claims. The compounds can be prepared using known compounds and intermediates of oxzolidinones, isoxazolines and butyolactones. The compounds are useful antibacterial agents, effective against a number of human and veterinary pathogens, including organisms which are known to be responsible for infection in persons with AIDS.
Patent NZ-502082-A (NZ)
Title: Optical fibre cable having high tracking resistance
Inventor: CASIRAGHI FLAVIO
IPC: G02B6/48
Filed: 1998-07-09
Abstract: An optical fiber cable having high tracking resistance, comprising at least one optical fibre (6) and a polymer-based extruded double-layer outer sheath (4).  The outer sheath comprises a first inner polymer layer (4a) substantially without tracking resistance, and a second outer polymer layer (4b) having characteristics of high tracking resistance, obtainable by adding a predetermined quantity of an inorganic oxide, in the hydrated or hydroxide form, to the polymer matrix. In this way it is possible to produce an optical fiber cable which has high tracking resistance, is light, has high mechanical strength, and is particularly suitable for installation along high-voltage overhead lines.
Patent NZ-502850-A (NZ)
Title: Waste outlet device
Inventor: MITCHELL GEOFF JOHN
IPC: E03C1/298
Filed: 1998-07-28
Abstract: A urinal bowl waste outlet device including a one-way valve means mountable so as to be removed from within the urinal bowl.  The one-way valve means is openable to allow the passage of waste fluid from the urinal bowl and closable to block the passage of gas in an upstream direction, wherein the one-way valve means does not trap fluid within the device.   The one-way valve means opens by means of an automatic reversible deformation in shape.
Patent NZ-502909-A (NZ)
Title: Measurement directed hard handoff controlled at mobile switching center
Inventor: BAKER KENNETH R
IPC: H04Q7/22
Filed: 1997-05-22
Abstract: Communications between a mobile and first and second base stations in a cellular system are directed by measuring the round trip delay of an active communication signal between the first base station and the mobile and entering a measurement directed hard handoff state by an active communication control unit located in a first mobile switching center of the system.  The active communication control unit accesses a measurement directed hard handoff table to determine, on the basis of the measured round trip delay corresponding to the first active communication signal, whether the location of the mobile corresponds to an area where handoff is desirable, that is handoff will most likely not drop the communication in progress.
Patent NZ-504737-A (NZ)
Title: Absorbent article comprising continuous fibers called tow arranged so that the fibers are bonded to each other at points, spots or lines but otherwise substantially unbonded
Inventor: WIDLUND URBAN
IPC: A61F5/44
Filed: 1998-12-03
Abstract: An absorbent article comprises a liquid permeable topsheet, a liquid impervious backsheet and an absorbent body arranged between. The absorbent article comprises continuous fibers, called tow, which are spread out in a layer. The fibers are bonded to each other in points, spots or lines, in a bonding pattern but are otherwise substantially unbonded to each other.  The continuous fibers can be used as a liquid acquisition layer applied between the topsheet and the absorbent body, as a liquid pervious topsheet or as an integrated topsheet/liquid acquisition layer. The absorbent article may be a diaper, pant diaper, incontinence guard, sanitary napkin or wound dressing.
Patent NZ-508514-A (NZ)
Title: Substituted 3-thiocarbamoylpyrazoles
Inventor: HANSEN OLAF
IPC: C07D401/04
Filed: 1999-05-21
Abstract: Substituted 3-Thiocarbamoylpyrazoles of general formula (I), wherein; R1 is H2N-CS-; m is 0 or 1; n is 0, 1 or 2; R2 is optionally substituted alkyl, alkoxycarbonyl, alkylcarbonyl, phenyl, pyridyl.  When m = 0, R2 can also be hydroxyl, chlorosulphonyl, alkoxy, alkenyloxy, halogenoalkyl, halogenoalkenyl, halogenoalkoxy, halogenalkenyloxy, alkylcarbonyloxy, formyl or alkylsilylethinyl. R3 is hydrogen, amino, chlorine, bromine, iodine or  -NH-CO-R10, -NHR11, -OR12, -SR12  or  -NR13-CX-C(R14, R15, R16), wherein; R10 is alkyl, halogenoalkyl, alkoxyalkyl, or optionally substituted phenyl, phenoxy or pyridyl; R11 is alkyl, alkenyl, alkinyl, formyl, alkylcarbonyl, halogenoalkylcarbonyl or alkoxycarbonyl; R12 is alkyl, alkenyl, alkinyl, diaminoalkyl, optionally substituted phenylalkyl, or -P(=Y)(OR17)(SR18) wherein R17 and R18 are alkyl and Y is oxygen or sulphur; R13 is hydrogen, alkyl, alkoxyalkyl, propargyl, allyl, alkoxycarbonyl, alkylcarbonyl, optionally substituted benzyl or -CO-C(R14, R15, R16) R14 is hydrogen, alkyl, halogen, halogenoalkyl or optionally substituted phenyl. R15 is hydrogen, alkyl, halogen, halogenoalkyl, halogenoalkoxyalkyl, alkylthioalkyl, alkylsulfinylalkyl, alkoxyalkoxyalkyl, hydroxyl, alkoxycarbonylalkyl, alkoxy or R14 and R15 together with the carbon atom they are attached to are an optionally substituted 5 to 7 membered ring system. R16 is hydroxyl, alkoxy, halogenoalkoxy or alkoxyalkoxy. The compounds of formula (I) are useful as pesticides.
Patent NZ-509076-A (NZ)
Title: Pharmaceutical compositions comprising 2-quinolones
Inventor: JOSEPH BENOIT
IPC: C07D215/20
Filed: 1999-07-13
Abstract: 2-Quinolone derivatives of formula (I) or formula (Ia) that are used against the proliferation of clonogenic cells in tumors are disclosed, wherein: X = O, S, or N-NH-R7; R1 - R4 = H, OH, 1-4C alkyl, 1-4C alkoxy, -OCOR8, or a group derived from a sugar, such that at least one of R1 - R4 is other than H; R2 + R3 = form methylenedioxy; R5 = phenyl (optionally substituted by 1 to 3 times H, OH, 1- 4C alkoxy, -OCO-R8, phenyl(1-4C alkoxy), -O-SO2-R'8 or a group derived from a sugar; R6 = H, 1-4C alkyl, -COR9 or -A-R10; R6a = 1-4C alkyl, -COR9, or -A-R10; R4 + R6 = form -CO-CH2-CH2-; R7 = phenyl or pyridinyl; R8 = 1-4C alkyl; R'8 = 1-4C alkyl or trifluoromethyl; R9 = 1-4C alkyl; A = 1-4C alkylene; R10 = 5- or 6-membered heterocycle (with 1 to 4 times O, N or S), CN, -COOR11, -CONR12R13, -NR14R15 or -COR16; and R11-R16 = H, 1-4C alkyl or phenyl(1-4C alkyl).